AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

843.542

-12.845-1.50%

Number of Gainers:12

Number of Losers:17

Number of Flat:17

PE:- -

High:856.440

Open:856.387

Low:842.294

Close:856.387

Loading ...

Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%

MT Newswires Live

BUZZ-Australia's Invion drops to 1-week low on termination of share purchase agreement

BRIEF-Race Oncology Executes A$8.6M Contract

BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand

Xanamem: Alzheimer’s breakthrough set for 2025, 2026

The Market Herald

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Simply Wall St.

Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs

THOMSON REUTERS

Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients

THOMSON REUTERS

Australian shares decline, dragged by banks and miners, as Trump tariffs kick off

Invion raises $2M in share placement to support cancer research work

The Market Herald

Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

Wrong button: Biotron explains to ASX why possible bankruptcy wasn’t price sensitive

The Market Herald

BRIEF-Dimerix Receives Initial Upfront Payment From FUSO

BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement

CSL Ltd - CSL Seqirus & Esperion Sign Licensing Agreement to Commercialise Nexletol and Nexlizetin Australia & New Zealand

THOMSON REUTERS

BRIEF-Imugene Ltd Appoints Darren Keamy As CFO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK7508/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":843.54193,"timestamp":1741582799994,"preClose":856.387,"halted":0,"volume":81305322,"delay":0,"changeRate":-0.014999,"change":-12.845093,"amount":116338255,"amplitude":0.016518,"prevYearClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":856.43976,"amplitude":0.016518,"preClose":856.387,"low":842.2942,"latestPrice":843.54193,"volume":81305322,"delay":0,"open":856.387,"prevYearClose":936.801,"prevWeekClose":856.387,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"sixtyDayClose":933.014,"secType":"PLATE","market":"AU","turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75,"timestamp":1741582799994,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":17,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517953396","title":"Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517953396","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517953396?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:58","pubTimestamp":1741143496,"startTime":"0","endTime":"0","summary":"Immuron  entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.Company shares were down nearly 3% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","BK7067","XAO.AU","XJO.AU","IMC.AU"],"gpt_icon":0},{"id":"2517958069","title":"BUZZ-Australia's Invion drops to 1-week low on termination of share purchase agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2517958069","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517958069?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:57","pubTimestamp":1741143476,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Invion drops to 1-week low on termination of share purchase agreement** Shares of Invion IVX.AX fall 3.7% to A$0.130, their lowest levels since February 25** The life sciences co issues a termination notice for the share purchase agreement with Lind Global Fund, dated June 27, 2024** The agreement is a private placement of A$100,000  every month over 12 months from June 2024** Co to repay the latest instalment to Lind Global** Invion stock on track for a third consecutive day of losses** Stock down 53.6% YTD, including current session's moves     ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO0DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","BK7096","BK7508","IVX.AU"],"gpt_icon":0},{"id":"2517939073","title":"BRIEF-Race Oncology Executes A$8.6M Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2517939073","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517939073?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:16","pubTimestamp":1741137407,"startTime":"0","endTime":"0","summary":"BRIEF-Race Oncology Executes A$8.6M Contract March 5 (Reuters) - Race Oncology Ltd RAC.AX:RACE EXECUTES A$8.6M CONTRACT TO SUPPORT PHASE 1 TRIAL OF RC220 IN SOLID TUMOUR PATIENTSFurther company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2517107939","title":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2517107939","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517107939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:10","pubTimestamp":1741137041,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand March 5 (Reuters) - Immuron Ltd IMC.AX:EXCLUSIVE DISTRIBUTION AGREEMENT FOR AUSTRALIA AND NEW ZEALAND TO LAUNCH PROIBSFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2517395908","title":"Xanamem: Alzheimer’s breakthrough set for 2025, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517395908","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517395908?lang=en_us&edition=fundamental","pubTime":"2025-03-05 08:00","pubTimestamp":1741132800,"startTime":"0","endTime":"0","summary":"The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare. In 2025, Australian biotech company Actinogen Medical Ltd  is making significant strides in tackling this issue with its groundbreaking therapy, Xanamem.Actinogen has entered the new year with a major milestone: The World Health Organisation  granted Xanamem a medical, non-proprietary name – “emestedastat” – cementing its status as a novel treatment candidate.This key recognition not only validates the drug’s potential but also marks it as the first in a new class of medications designed to regulate brain cortisol levels; a critical factor in Alzheimer’s progression.“Based on positive outcomes in Phase 2 trials with the 10mg daily dose of Xanamem in both Alzheimer’s and major depression, we have strong confidence in the drug’s potential to drive meaningful progress in future trials.”The trial’s primary endpoint is the Clinical Dement","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/xanamem-alzheimers-breakthrough-set-for-2025-2026-2025-03-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2517084959","title":"Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517084959","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517084959?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:35","pubTimestamp":1741131340,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/heres-why-were-not-too-worried-about-actinogen-medicals-asxa-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2517998720","title":"Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998720?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:51","pubTimestamp":1741128672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2517984985","title":"Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984985?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:58","pubTimestamp":1741125537,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2516661278","title":"Australian shares decline, dragged by banks and miners, as Trump tariffs kick off","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661278?lang=en_us&edition=fundamental","pubTime":"2025-03-04 14:05","pubTimestamp":1741068324,"startTime":"0","endTime":"0","summary":"Australian shares decline, dragged by banks and miners, as Trump tariffs kick offUpdates to market closeAustralia's benchmark ASX200 slips 0.6% amid trade war fearsBanks fall 0.5%, miners fall 0.7%New Zealand benchmark falls 0.6%By Nikita Maria Jino","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN0D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7508","BK7095","BK7507","MQG.AU","BHP.AU","BK7511","BK7501","BK7046","NAB.AU","BK7135"],"gpt_icon":0},{"id":"2516642665","title":"Invion raises $2M in share placement to support cancer research work","url":"https://stock-news.laohu8.com/highlight/detail?id=2516642665","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516642665?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:46","pubTimestamp":1741059960,"startTime":"0","endTime":"0","summary":"Biotech company Invion Ltd  is raising $2 million in a two-tranche share placement to support a series of clinical trials and development activities for its Photosoft technology, seeking to treat a range of cancers.The company said it had completed the placement, with shares priced at 14 cents each – a 2.5% premium to the 30-day volume-weighted average price. This was chiefly managed by Blue Ocean Equities and has already attracted strong demand – reflected in the fact the initial goal was $1.5 million.The funds will go towards recruiting from a second site for the company’s Phase I/II skin cancer trial, and commencement of a Phase I/II anogenital trial in collaboration with the Peter MacCallum Cancer Centre in Melbourne.Crucially, a successful outcome in the latter could enable orphan drug designation in the U.S. to fast-track trials in the rare disease indications.The material provided in this article is for information only and should not be treated as investment advice. Viewers are","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/invion-raises-2m-in-share-placement-to-support-cancer-research-work-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IVX.AU","BK7509","BK7508","BK7096"],"gpt_icon":0},{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","XJO.AU","XKO.AU","BK7501","DXB.AU","DMX","XAO.AU"],"gpt_icon":0},{"id":"2516613662","title":"Wrong button: Biotron explains to ASX why possible bankruptcy wasn’t price sensitive","url":"https://stock-news.laohu8.com/highlight/detail?id=2516613662","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516613662?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:23","pubTimestamp":1741058580,"startTime":"0","endTime":"0","summary":"Biotron  has been forced to explain its position to ASX Compliance after being queried by the regulator over why it didn’t classify as ‘price sensitive’ an announcement foreshadowing potential bankruptcy.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.Human error. Literally – the company ticked the wrong box.“The announcement was considered by the company to be market sensitive… Unfortunately, during lodgement of the announcement, the wrong box… was pressed. This was a human error,” Biotron wrote on Tuesday.As for additional concerns that the company didn’t make price sensitive a share purchase plan announcement, there too the regulator is worrying unduly – because Biotron made it clear it’s since changed that to a rights issue.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wrong-button-biotron-explains-to-asx-why-possible-bankruptcy-wasnt-price-sensitive-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7501","BK7067","BIT.AU"],"gpt_icon":0},{"id":"2516269987","title":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:23","pubTimestamp":1741051414,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSOMarch 4  - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF 300 MILLION FROM FUSO PHARMACEUTICAL INDUSTRIESDIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM FUSOANTICIPATES A FURTHER 400 MILLION FROM FUSOFurther company coverage: DXB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2516696895","title":"BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516696895","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516696895?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:01","pubTimestamp":1741050092,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement March 4 (Reuters) - CSL Ltd CSL.AX:CSL SEQIRUS & ESPERION SIGN LICENSING AGREEMENT TO COMMERCIALISE NEXLETOL AND NEXLIZET IN AUSTRALIA & NEW ZEALANDFurther company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2516695406","title":"CSL Ltd - CSL Seqirus & Esperion Sign Licensing Agreement to Commercialise Nexletol and Nexlizetin Australia & New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2516695406","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516695406?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:54","pubTimestamp":1741049681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"gpt_icon":0},{"id":"2516693550","title":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693550?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:25","pubTimestamp":1741047942,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO March 4 (Reuters) - Imugene Ltd IMU.AX:APPOINTS DARREN KEAMY AS CFO AND COMPANY SECRETARYMIKE TONROE RESIGNS AS CFOFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":11,"pageCount":4,"totalSize":173}]}}